Skip to main content
Amanda Olson, MD, Oncology, Houston, TX, University of Texas M.D. Anderson Cancer Center

AmandaLeighOlsonMD

Oncology Houston, TX

Assistant Professor, Stem Cell Transplant and Cellular Therapy, MD Anderson Cancer Center

Dr. Olson is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Olson's full profile

Already have an account?

Education & Training

  • Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2010 - 2013
  • Baylor College of Medicine
    Baylor College of MedicineResidency, Internal Medicine, 2007 - 2010
  • Medical College of Georgia at Augusta University
    Medical College of Georgia at Augusta UniversityClass of 2007

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2021 - Present
  • TX State Medical License
    TX State Medical License 2013 - 2025
  • WA State Medical License
    WA State Medical License 2023 - 2025
  • AZ State Medical License
    AZ State Medical License 2023 - 2025
  • OK State Medical License
    OK State Medical License 2020 - 2024
  • MS State Medical License
    MS State Medical License 2023 - 2024
  • AL State Medical License
    AL State Medical License 2023 - 2024
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • A Randomized Study of Fludarabine-Clofarabine Vs Fludarabine Alone Combined with Busulfan and Allogeneic Hematopoietic Transplantation for AML and MDS
    Amanda L. Olson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Allogeneic Cord Blood Regulatory T Cells Can Prevent Graft Vs. Host Disease and Preserve Graft Vs Leukemia Effect: Update on Phase I/II Clinical Trial
    Amanda L. Olson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Allogeneic Hematopoietic Cell Transplantation May Improve Long-Term Outcomes in Patients with Ph-like Acute Lymphoblastic Leukemia with CRLF2 Overexpression
    Amanda L. Olson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Join now to see all

Lectures

  • Third-Party BK Virus Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Donor NKG2C Copy Number: An Independent Predictor for CMV Reactivation after Double Cord Blood Transplantation 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • Outcomes in Patients with CRLF2 Overexpressed Acute Lymphoblastic Leukemia After Allogeneic Hematopoietic Cell Transplantation
    Outcomes in Patients with CRLF2 Overexpressed Acute Lymphoblastic Leukemia After Allogeneic Hematopoietic Cell TransplantationMarch 25th, 2021
  • Myelodysplastic Syndrome Survivor: Why I’ve Been Giving My Care Team Sacagawea Coins
    Myelodysplastic Syndrome Survivor: Why I’ve Been Giving My Care Team Sacagawea CoinsJune 18th, 2020

Professional Memberships

Hospital Affiliations